Critical evaluation of ceftolozane–tazobactam for complicated urinary tract and intra-abdominal infections

Keyphrases

• Intra-abdominal Infection 100%
• Urinary Tract 100%
• Ceftolozane 100%
• Recurrent Urinary Tract Infections (rUTIs) 80%
• Complicated Intra-abdominal Infection (cIAI) 80%
• Multidrug-resistant Pseudomonas Aeruginosa (MDRPA) 40%
• Metronidazole 40%
• Gram-negative Pathogens 40%
• ESBL-producing Enterobacteriaceae 40%
• Tazobactam 40%
• Moderate to Severe 20%
• Phase II Trial 20%
• Pharmacokinetics-pharmacodynamics (PK-PD) 20%
• Protein Binding 20%
• Pharmacodynamics 20%
• Minimum Inhibitory Concentration 20%
• Lactams 20%
• Effective Alternative 20%
• Dose Rate 20%
• High Affinity 20%
• Phase III Clinical Trial 20%
• U.S. Food 20%
• Penicillin-binding Proteins 20%
• Hydrolysis 20%
• Extended-spectrum-lactamase 20%
• β-lactamase 20%
• Safer Alternatives 20%
• Bacteroides Fragilis 20%
• New Antimicrobials 20%
• Low Protein 20%
• Resistant Infection 20%
• Dosage Adjustment 20%
• Severe Renal Impairment 20%
• Alternative Agents 20%
• Repeated Dosing 20%
• Nosocomial Pneumonia 20%
• β-lactamase Inhibitor 20%
• Inhibitor Combination 20%
• Streptococcal Species 20%
• Linear Pharmacokinetics 20%
• PBP3 20%
• Carbapenem-sparing 20%
• PBP1b 20%
• Free Drug Concentration 20%
• Anaerobic Coverage 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Abdominal Infection 100%
• Ceftolozane 100%
• Urinary Tract Infection 80%
• Infection 60%
• Penicillinase 60%
• Infectious Agent 40%
• Metronidazole 40%
• Pharmacokinetics 40%
• Pseudomonas aeruginosa 40%
• Tazobactam 40%
• Extended Spectrum Beta Lactamase Producing Enterobacteriaceae 40%
• Clinical Trial 20%
• Pharmacodynamics 20%
• Protein Binding 20%
• Minimum Inhibitory Concentration 20%
• Drug Concentration 20%
• Lactam 20%
• Antiinfective Agent 20%
• Bacteroides fragilis 20%
• Carbapenem 20%
• Severe Renal Impairment 20%
• Penicillin Binding Protein 20%